Stocks · News reference
Zai Lab Says FDA Grants Orphan Drug Designation To Zocilurtatug Pelitecan, Delta-Like Ligand 3 Antibody-Drug Conjugate, For Treatment Of Neuroendocrine Carcinomas
- NECs are aggressive malignancies with poor prognoses and limited treatment options, representing significant unmet patient need- U.S. FDA Orphan Drug Designation (ODD) follows receipt of ODD for zoci in pulmonary NECs
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript
Zai Lab (NASDAQ:ZLAB) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to earnings
The Insider Report: The Leaders Have Taken Off
Market Overview Stocks began their breakout to new all-time highs again, but it remains a highly selective environment. Only the Nasdaq hit a record high, as it finished up 2.06% on the week, and outperformed for the
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. futures rose, while Limoneira fell 8.4% after missing earnings and sales estimates. Resolution Minerals and Cooper led other premarket decliners.